We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




e-Incubator Technology Provides Real-Time Imaging of Bioengineered Tissues in a Controlled Unit

By LabMedica International staff writers
Posted on 24 Nov 2014
A new e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under a controlled setting and to study their growth and development in real time without risk of contamination or damage. More...


Offering the potential to test engineered tissues before human transplantation increases the success rate of implantation, and accelerates the translation of tissue engineering methods from the lab to the clinic, the novel e-incubator was described in the journal Tissue Engineering, Part C.

Shadi Othman, PhD, Karin Wartella, PhD, Vahid Khalilzad Sharghi, and Huihui Xu, PhD, from the University of Nebraska-Lincoln (USA), presented their findings of a validation study using the device to culture tissue-engineered bone constructs for four weeks. The e-incubator is a standalone unit that automatically detects and regulates internal conditions such as temperature, carbon dioxide levels, and pH via a microcontroller. It performs media exchange to feed the cultures and remove waste products. The current design is compatible with MRI to monitor the constructs without removing them from the incubator. With proper adjustments, compatibility with other imaging technologies including computed tomography [CT] and optical imaging is also possible.”

“Calibratable, hands-free tissue development environments are becoming increasingly important for the engineering of implantable tissues,” said Tissue Engineering co-editor-in-chief Peter C. Johnson, MD, vice president, research and development, Avery Dennison Medical Solutions (Chicago, IL, USA), and president and CEO, Scintellix, LLC (Raleigh, NC, USA). “In this new development, noninvasive imaging modalities are added to the spectrum of sensing and environmental capabilities that heretofore have included temperature, humidity, light, physical force, and electromagnetism. This represents a solid advance for the field.”

Related Links:

University of Nebraska-Lincoln



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.